10X Genomics

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, ATAC, and Genome. The company was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

10X Genomics reports solid earnings, eyes growth through innovation

10X Genomics delivered solid earnings in Q4 2022, with revenue growth and strong product innovation driving market presence and customer engagement.
Despite challenges like operational constraints and margin expectations, the company focuses on financial sustainability and market adaptability for future growth.
Opportunities lie in new sample types exploration, product success with Xenium and Visium HD, and customer response to Chromium Flex, indicating potential for revenue growth and market expansion.
Balanced guidance discussions and a focus on key products position 10X Genomics for strategic growth in 2023, with a global market outlook and emphasis on innovation and customer satisfaction.

10x Genomics reports robust Q1 revenue growth, eyes operational efficiency

10x Genomics delivered strong revenue growth in Q1 2023, driven by spatial portfolio and Chromium consumables, with raised revenue guidance for the year.
The company faces challenges in China and margin pressures but sees opportunities in product enhancements, market expansion, and revenue diversification.
Overall, 10x Genomics is strategically positioned for growth, with a focus on operational efficiency, customer adoption, and revenue optimization.

10X Genomics reports robust Q2 growth amidst China challenges

10X Genomics saw strong revenue growth in Q2 2023, driven by single cell and spatial portfolios.
While facing challenges in China, opportunities lie in expanding applications and clinical adoption.
Operational improvements and product advancements position the company for future growth.
Focus on margin improvement and revenue diversification key for sustained success.

10x Genomics reports robust Q3 revenue growth and strategic realignment

10x Genomics showcased strong revenue growth driven by Xenium's success, with plans to enhance product offerings and rebalance resources for future growth.
Despite challenges in gross margin and flat Chromium revenue, the company remains optimistic about its outlook and growth potential in spatial placements.
Opportunities lie in leveraging Xenium's capabilities, driving consumable revenue through discounts, and focusing on the Chromium franchise for sustained growth.

10x Genomics reports strong Q4 earnings, eyes growth opportunities

10x Genomics anticipates revenue of $670-690 million for 2024.
Guidance philosophy balances upsides and downsides for growth.
Strategic focus on product portfolio and long-term gross margin profile.
Emphasis on investments for future growth and maintaining innovation.

10x Genomics reports Q1 revenue growth, tackles pricing challenges

10x Genomics saw strong revenue growth in spatial but faced challenges with new Chromium technology orders.
The company aims to drive adoption by reducing prices and expanding the total market for single-cell technology.
Customers are showing interest in multiple platforms, setting up genomics infrastructure with various use cases.
Despite obstacles, 10x Genomics remains optimistic about the potential of its technology platforms and market growth.

10X Genomics reports Q3 revenue decline, focuses on growth strategies

10X Genomics faced revenue decline in Q3 due to sales restructuring and cautious customer spending, with full-year revenue expected to decline by 3%. Despite challenges, the company is focused on driving growth through new product launches, evolving commercial structure, and expanding access to single cell analysis. Confidence in the company's path forward remains strong, with expectations for sequential improvements and a focus on long-term opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PLEASANTON, Calif., Dec. 1, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that Chromium X has been named one of The Scientist's 2021 Top 10 Innovations, an annual list of newly released products that have the potential to generate the biggest impact on scientific research.

10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year

After a hot start, the stock has recently lagged the market. Is now a good time to buy?

10x Genomics Stock: Bull vs. Bear

DermTech Inc

Both companies offer disruptive new solutions in their niches of the healthcare space.

Better Buy: 10x Genomics vs. DermTech

10x Genomics Inc (NASDAQ: TXG) reported Q3 sales of $125.3 million, beating the consensus of $122.62 million. Sales increased 74% Y/Y, primarily due to increased consumables revenue driven by growth in the instrument installed base.

10x Genomics Clocks 74% Jump In Q3 Revenues; Raises Top End Of Sales Guidance

PLEASANTON, Calif., Nov. 3, 2021 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2021.

10x Genomics Reports Third Quarter 2021 Financial Results

10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.

10x Genomics Earnings Preview

SINGAPORE, Oct. 25, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today marked a major Asia Pacific (APAC) expansion with the grand opening celebration of its Singapore manufacturing facility and commercial hub. The addition of the company's first manufacturing facility outside the U.S. is part of 10x Genomics' ongoing investments to integrate and scale its operations network to build a more robust supply chain and better serve customers globally.

10x Genomics Celebrates Opening of Singapore Manufacturing and Commercial Hub

The mean of analysts' price targets for 10x Genomics (TXG) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 27% Upside in 10x Genomics (TXG): Can the Stock Really Move This High?

Atea Pharmaceuticals

Doximity

Our trio of contributors offer three COVID-19 stocks that will zoom higher, even as we emerge from the pandemic.

3 COVID Stocks That Can Turn $1,000 Into $10,000

PLEASANTON, Calif., Oct. 7, 2021 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2021 after market close on Wednesday, November 3rd, 2021.

10x Genomics to Report Third Quarter Financial Results on November 3, 2021

Inspire Medical Systems Inc

Omnicell

Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.

Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges

10x Genomics (TXG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Here's Why 10x Genomics (TXG) is Poised for a Turnaround After Losing 22.3% in 4 Weeks

10x Genomics (NASDAQ:TXG) shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral and announced a $180 price target. 10x Genomics' stock is currently down 7.53% to a price of $156.27.

Why 10x Genomics Shares Are Trading Lower Today

PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2021 Results - Earnings Call Transcript

Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

PLEASANTON, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th, 2021. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

10x Genomics to Report Second Quarter Financial Results on August 4, 2021

Shopify

Even with some setbacks in 2021, the ARK Invest manager has still found some winners.

These 3 Cathie Wood Stocks Are Still Going Strong

10x Genomics, Inc. is a global life sciences technology company developing innovative biological products from their cross-functional expertise across biology, chemistry, software, and hardware with a broad global customer base. 10x Genomics offers a variety of applications and products for customers to analyze biological systems at fundamental resolutions on massive scales covering instruments, consumables, and software.

10x Genomics: Promising Growth From A Life Science Leading Single Cell Specialist

Long-term investors should keep perspective.

Here's Why 10x Genomics Can't Satisfy Short-Term Investors

10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in 10x Genomics (TXG): Can Its 3.9% Jump Turn into More Strength?

SoftBank Group Corp

Coupang

DoorDash

NVIDIA

Uber

Qualtrics International

Zymergen

Tech stocks are on display in Softbank's Vision Fund. These seven are among the best ones, now public, to consider investing in.

7 Best Tech Stocks Pumped Out by Softbank's ‘Golden Egg' Machine

10x Genomics stock has fallen, despite announcing strong first-quarter numbers.

Down More Than 20%, Is This Cathie Wood Biotech A Buy?

Shares of 10x Genomics (NASDAQ:TXG) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 186.96% over the past year to $0.66, which beat the estimate of $0.50.

Recap: 10x Genomics Q1 Earnings

The company delivered tremendous revenue growth but a deteriorating bottom line.

News for 10X Genomics Stock (TXG)